Development of a novel targeting therapy using anti-podoplanin antibody against malignant pleural mesothelioma
| Project/Area Number |
25460189
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | The University of Tokushima |
|---|
Principal Investigator |
ABE Shinji 徳島大学, 大学院医歯薬学研究部, 助教 (00403717)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NISHIOKA Yasuhiko 徳島大学, 大学院医歯薬学研究部, 教授 (70274199)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | トランスレーショナルリサーチ / 抗体医薬 / ADCC / ポドプラニン / 個別医療 / 悪性胸膜中皮腫 |
|---|
| Outline of Final Research Achievements |
Malignant pleural mesothelioma (MPM) is mainly caused by exposure to asbestos, develops in the pleural cavity with a high likelihood of malignancy. Development of novel therapies for MPM is warranted in order to improve very poor prognosis. In this study, we investigated whether anti-human podoplanin antibodies can induce antitumor effects in MPM. Using podoplanin positive human MPM cell lines, anti-human podoplanin antibodies with NK cells induced significant antitumor effect. Our results strongly suggest that anti-human podoplanin antibodies might provide an efficacious therapeutic strategy for the treatment of MPM.
|
Report
(4 results)
Research Products
(6 results)
